Significant improvements in waist circumference and multiple cardiometabolic risk factors
Tsou SH, Luo KS, Huang CN, et al
On 21 May 2026 , Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks , with 45.3% of patients losing 30% or more a threshold previously only achievable with bariatric surgery
Buy Retatrutide (R-30, 30mg) Affiliate link we may earn a commission at no extra cost to you
YOUR RESULTS WHAT WE TREAT We treat the whole person, instead of just writing a script and hoping for the best
A systematic review and comparison of meta-analyses